Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)
08-03-2018

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND enters into license agreement to further develop novel treatments improving beta-cell health and insulin signalling with Novo Nordisk
13-12-2017

Leuven Belgium, December 14th, 2017: reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic program of diabetes. This program holds also promise for NASH and the metabolic syndrome.

Read more
reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s
14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively.
Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
23-06-2015
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
05-05-2014
reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
27-03-2014
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more
The strategic alliance between Roche and reMYND is nominated for a Scrip Award
07-02-2014
The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”.
Read more
reMYND receives a positive tax ruling on the income from its Roche collaboration
31-01-2012
reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.
Read more
reMYND’s grant from the Michael J Fox Foundation in SciBX
17-08-2011
The Science-Business eXchange devoted an article to the role the Michael J Fox Foundation has been playing in PD therapeutics.
Read more